Intestinal barrier integrity in patients with plaque psoriasis

Abstract Psoriasis is a chronic inflammatory systemic disease. Growing evidence suggests that human homeostasis depends on a mutualistic relationship with gut bacteria that produce a number of biologically active compounds. Therefore, enteric microbiota dysbiosis with gut barrier disruption may be an important factor in the development of chronic inflammatory diseases. The aim of our study was to assess non‐invasive markers of intestinal barrier integrity in patients with moderate to severe psoriasis. Concentrations of claudin‐3 (intestinal epithelial tight junction structure) and intestinal fatty acid binding protein (I‐ FABP ; marker of enterocyte damage) were determined in the blood of patients with chronic plaque psoriasis ( n = 20) and healthy individuals ( n = 20) using commercially available enzyme‐linked immunoassay test kits. Claudin‐3 concentration was higher in patients with psoriasis compared with healthy control (median, 54.07 vs 42.36 ng/mL; P < 0.001). Patients with psoriasis also had elevated concentration of plasma I‐ FABP (median, 708.8 vs 147.1 pg/mL; P < 0.05). Our results support the hypothesis that dysfunction of the intestinal barrier in psoriasis disturbs the homeostatic equilibrium between the microbiota and immune system. Further studies are needed in order to develop new therapeutic interventions based on modulation of intestinal permeability.